BC Extra | Aug 29, 2019
Politics & Policy

Clock ticking on Sharpless' term as acting FDA commissioner

Time may be running out on Ned Sharpless’ term as acting FDA commissioner. President Donald Trump must make a decision about the agency's top job by Nov. 1. If the White House decides to seek...
BC Week In Review | Jun 15, 2015
Clinical News

EP-100: Phase II data

The open-label, U.S. Phase II ESP2011-002 trial in 44 evaluable patients with advanced ovarian cancer showed that IV EP-100 plus paclitaxel led to an ORR, the primary endpoint, of 34.8% vs. 33.3% for paclitaxel alone....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

Genzyme Ventures reboot After a slow integration period, Sanofi-Genzyme BioVentures is looking to make up to five investments per year in early stage companies that align with the focus of parent Sanofi (Euronext:SAN; NYSE:SNY). The...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
BC Week In Review | Jun 11, 2012
Clinical News

EP-100: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 38 patients with LHRH-positive solid tumors showed that twice-weekly IV EP-100 for 3 weeks of a 4-week cycle was generally well tolerated and led to 5 cases...
BC Week In Review | May 28, 2012
Clinical News

EP-100: Phase II started

Esperance began an open-label, U.S. Phase II trial (ESP2011-002) to compare an IV infusion of EP-100 twice weekly for the first 3 weeks of a 4-week cycle for up to 6 cycles plus weekly IV...
BC Week In Review | Jun 13, 2011
Financial News

Esperance completes venture financing

Esperance Pharmaceuticals Inc. , Baton Rouge, La.   Business: Cancer   Date completed: 6/1/11   Type: Venture financing   Raised: Not disclosed   Investors: Sanofi ; Louisiana Fund; Themelios Ventures Partners; Research Corp. Technologies; Advantage Capital...
BC Innovations | Apr 21, 2011
Strategy

A conversation with Gregory Verdine

What will drugs look like in the coming decade? This is the question being posed by Gregory Verdine and the next-generation therapeutic modalities team he leads at Third Rock Ventures . One answer, Verdine believes, is...
BC Week In Review | Sep 14, 2009
Clinical News

EP-100: Phase I started

Esperance began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous EP-100 given for 3 weeks of a 4-week cycle in up to 36 patients. Esperance Pharmaceuticals Inc. , Baton Rouge, La.   Product: EP-100...
BC Week In Review | Apr 27, 2009
Clinical News

Esperance preclinical data

In a mouse xenograft model of ovarian cancer, weekly injections of EP-100 at doses as low as 0.2 mg/kg led to significant tumor regression from baseline (p<0.03), while tumor growth was observed in mice receiving...
Items per page:
1 - 10 of 14
BC Extra | Aug 29, 2019
Politics & Policy

Clock ticking on Sharpless' term as acting FDA commissioner

Time may be running out on Ned Sharpless’ term as acting FDA commissioner. President Donald Trump must make a decision about the agency's top job by Nov. 1. If the White House decides to seek...
BC Week In Review | Jun 15, 2015
Clinical News

EP-100: Phase II data

The open-label, U.S. Phase II ESP2011-002 trial in 44 evaluable patients with advanced ovarian cancer showed that IV EP-100 plus paclitaxel led to an ORR, the primary endpoint, of 34.8% vs. 33.3% for paclitaxel alone....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

Genzyme Ventures reboot After a slow integration period, Sanofi-Genzyme BioVentures is looking to make up to five investments per year in early stage companies that align with the focus of parent Sanofi (Euronext:SAN; NYSE:SNY). The...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
BC Week In Review | Jun 11, 2012
Clinical News

EP-100: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 38 patients with LHRH-positive solid tumors showed that twice-weekly IV EP-100 for 3 weeks of a 4-week cycle was generally well tolerated and led to 5 cases...
BC Week In Review | May 28, 2012
Clinical News

EP-100: Phase II started

Esperance began an open-label, U.S. Phase II trial (ESP2011-002) to compare an IV infusion of EP-100 twice weekly for the first 3 weeks of a 4-week cycle for up to 6 cycles plus weekly IV...
BC Week In Review | Jun 13, 2011
Financial News

Esperance completes venture financing

Esperance Pharmaceuticals Inc. , Baton Rouge, La.   Business: Cancer   Date completed: 6/1/11   Type: Venture financing   Raised: Not disclosed   Investors: Sanofi ; Louisiana Fund; Themelios Ventures Partners; Research Corp. Technologies; Advantage Capital...
BC Innovations | Apr 21, 2011
Strategy

A conversation with Gregory Verdine

What will drugs look like in the coming decade? This is the question being posed by Gregory Verdine and the next-generation therapeutic modalities team he leads at Third Rock Ventures . One answer, Verdine believes, is...
BC Week In Review | Sep 14, 2009
Clinical News

EP-100: Phase I started

Esperance began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous EP-100 given for 3 weeks of a 4-week cycle in up to 36 patients. Esperance Pharmaceuticals Inc. , Baton Rouge, La.   Product: EP-100...
BC Week In Review | Apr 27, 2009
Clinical News

Esperance preclinical data

In a mouse xenograft model of ovarian cancer, weekly injections of EP-100 at doses as low as 0.2 mg/kg led to significant tumor regression from baseline (p<0.03), while tumor growth was observed in mice receiving...
Items per page:
1 - 10 of 14